Shionogi/GSK HIV integrase inhibitor looks good at Phase II
This article was originally published in Scrip
Executive Summary
Shionogi and GlaxoSmithKline have released the first clinical data for an oral HIV integrase inhibitor they are jointly developing, which suggest it may be effective in once-daily doses without an added booster.